For the treatment of primary hypercholesterolemia, mixed dyslipidemia, and severe hypertriglyceridemia as adjunctive therapy to diet

In the field of treatment options,
all fenofibrates are not created equal*

0

Capsules shown are not actual size.

*ANTARA® provides substantial support programs as compared to other generic products.

The Consequences of Poor Patient Adherence

Patient adherence influences the Success or Failure of a treatment regimen.

How can you help patients comply?

Give Your Patients Efficacy with Compliance-Enhancing Features

Learn more

ANTARA® provides a 37% reduction in TG and a 14% increase in HDL-C1

View the data

Help your eligible patients save

Big savings, No Co-Pay, Refill Reminders!

Learn More

Reference
  1. Davidson MH, Bays H, Rhyne J, et al. Efficacy and safety profile of fenofibrate-coated microgranules 130 mg, with and without food, in patients with hypertriglyceridemia and the metabolic syndrome: an 8-week, randomized, double-blind, placebo-controlled study. Clin Ther. 2005;27(6):715-727.